Stockscreener 앱 받기
0.3047
5.84%
-0.0189
전일 마감가:
$0.3236
열려 있는:
$0.319
하루 거래량:
318.95K
Relative Volume:
0.83
시가총액:
$24.88M
수익:
$391.70K
순이익/손실:
$-52.34M
주가수익비율:
-0.4063
EPS:
-0.75
순현금흐름:
$-45.92M
1주 성능:
-12.94%
1개월 성능:
+8.20%
6개월 성능:
-75.62%
1년 성능:
-90.04%
1일 변동 폭
$0.3004
$0.3305
1주일 범위
$0.3004
$0.3573
52주 변동 폭
$0.2425
$3.4258
Ovid Therapeutics Inc Stock (OVID) Company Profile
명칭
Ovid Therapeutics Inc
전화
212-776-4381
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
OVID을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.3047 | 24.88M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 개시 | B. Riley Securities | Buy |
| 2024-04-29 | 개시 | H.C. Wainwright | Buy |
| 2024-04-05 | 개시 | Wedbush | Outperform |
| 2023-12-21 | 개시 | BTIG Research | Buy |
| 2023-10-13 | 개시 | Oppenheimer | Outperform |
| 2021-04-20 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2018-04-20 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Dup15q syndrome Market: Epidemiology, Therapies, Companies, - openPR.com
JPMorgan Chase & Co. Decreases Stock Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Upgraded at William Blair - Defense World
Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Target Price at $3.03 - Defense World
Ovid Therapeutics Inc [OVID] stock for 2,956 USD was sold by ALEXANDER MARGARET A. - knoxdaily.com
The OVID Stock Puzzle: Unraveling Ovid Therapeutics Inc’s Fluctuating Performance - investchronicle.com
A closer look at Ovid Therapeutics Inc (OVID) is warranted - uspostnews.com
Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium | Libero Quotidiano.it - Libero Quotidiano
Dravet Syndrome Treatment Market Future Business - openPR.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ovid Therapeutics stock hits 52-week low at $0.27 By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.27 - Investing.com
In Vivo’s 2025 Rising Leaders - insights.citeline.com
Ovid Therapeutics Advances Pipeline Amid Financial Progress - TipRanks
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Brain Medicine Updates: Ovid Therapeutics Takes Center Stage at Major Healthcare Conference - Stock Titan
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $3.03 Consensus Target Price from Brokerages - Defense World
Ovid Therapeutics stock hits 52-week low at $0.35 amid downturn By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.35 amid downturn - Investing.com Canada
HC Wainwright Lifts Earnings Estimates for Ovid Therapeutics - Defense World
FY2026 Earnings Forecast for OVID Issued By HC Wainwright - Defense World
Ovid Therapeutics (NASDAQ:OVID) Price Target Lowered to $4.00 at BTIG Research - Defense World
Ovid Therapeutics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Australia
Ovid Therapeutics stock target cut to $2 at H.C. Wainwright - Investing.com
BTIG cuts Ovid Therapeutics stock price target to $4 By Investing.com - Investing.com South Africa
BTIG cuts Ovid Therapeutics stock price target to $4 - Investing.com
Ovid Therapeutics stock hits 52-week low at $0.42 amid market challenges - Investing.com
Ovid Therapeutics stock hits 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa
West syndrome Pipeline 2025: Mechanism of Action, Route - openPR
Q1 EPS Forecast for Ovid Therapeutics Raised by Analyst - Defense World
What is Wedbush’s Estimate for OVID FY2029 Earnings? - Defense World
William Blair Forecasts Lower Earnings for Ovid Therapeutics - Defense World
What is William Blair’s Estimate for OVID Q1 Earnings? - Defense World
Wedbush Adjusts Price Target on Ovid Therapeutics to $3 From $4, Keeps Outperform Rating - MarketScreener
Ovid Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
Ovid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies - TipRanks
Ovid Therapeutics stock plunges to 52-week low of $0.46 - Investing.com India
Ovid Therapeutics stock plunges to 52-week low of $0.46 By Investing.com - Investing.com South Africa
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ovid Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Ovid Therapeutics Secures 2-Year Cash Runway as 3 Novel Drug Programs Progress - StockTitan
We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate - Yahoo Finance
Ovid Therapeutics (OVID) Expected to Announce Earnings on Friday - Defense World
Trump's FDA chief pick Makary to face overhauling agency, keeping Kennedy happy -March 06, 2025 at 06:00 am EST - Marketscreener.com
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.03 Consensus Target Price from Brokerages - Defense World
Ovid Therapeutics Inc (OVID) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):